Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...

Earnings season marches on, with Eli Lilly among the big names yet to report this week. President Trump has said he will name replacements this week for Federal Reserve governor Adriana Kugler and [Bu ...

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...

BRANCHBURG – Eli Lilly, a multinational pharmaceutical company headquartered in Indianapolis with $45 billion in annual sales, has confirmed that it is selling its facility on Imclone Lane off Route ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...